CollabRx Adjourns Stockholder Special Meeting to October

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CollabRx Adjourns Stockholder Special Meeting to October 30, 2015

SAN FRANCISCO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- CollabRx, Inc. ("CollabRx") (NASDAQ: CLRX ) announced today that the special meeting of its stockholders scheduled for Wednesday, October 28, 2015 to consider and act on several proposals recommended by CollabRx's board and management regarding its proposed merger with Medytox Solutions, Inc. ("Medytox") (OTCQB:MMMS) has been adjourned to Friday, October 30, 2015 at 10:30 am Pacific Time, and will take place at CollabRx's offices located at 44 Montgomery Street, Suite 800, San Francisco, CA 94104-4811.

The adjournment period will allow for the continued solicitation of proxies from CollabRx's stockholders with respect to Proposal 2 (reverse stock split) and Proposal 3 (increase in authorized common stock). As of October 28, 2015, an aggregate of 5,259,155 shares have been voted, which constitutes a quorum required to conduct business at the special meeting. Had the meeting today not been adjourned, based on the shares submitted as of October 28, 2015, Proposal 1 (issuance of shares in connection with the merger), Proposal 4 (amendment to stock plan), Proposal 5 (advisory vote) and Proposal 6 (adjournment of meeting) would have had sufficient votes to be approved at the special meeting. With regard to Proposal 2, there are currently 4,602,521 votes (representing 87.5% of the votes cast) "FOR" the proposal and 576,592 votes (representing 11.0% of the votes cast) "AGAINST" the proposal. With regard to Proposal 3, there currently 4,484,425 votes (representing 85.3% of the votes cast) "FOR" the proposal and 560,578 votes (representing 10.7% of the votes cast) "AGAINST" the proposal. The affirmative vote of at least 5,243,687 shares, representing a majority of CollabRx shares outstanding as of the close of business on the record date, is required to approve Proposal 2 and Proposal 3. It is a condition to the merger that Proposal 2 and Proposal 3 be approved. Unless Proposal 2 is approved, CollabRx's board and management believe that CollabRx will not be able to maintain the listing of its common stock on the NASDAQ Capital Market.

Stockholders who have already voted do not need to recast their votes. Proxies previously submitted will be voted at the reconvened meeting unless properly revoked. Stockholders who have not already voted or wish to change their vote are encouraged to do so using the instructions provided in their voting instruction form or proxy card.

CollabRx has filed a registration statement on Form S-4 including a definitive joint proxy statement/prospectus with the Securities and Exchange Commission. Stockholders as of the record date of September 4, 2015 who have not yet voted are encouraged to vote during the adjournment period. Additionally, stockholders are urged to read the definitive joint proxy statement/prospectus and other relevant information on file with the Securities and Exchange Commission.

Participants in Solicitation

CollabRx and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies from CollabRx stockholders with respect to the merger. Information about CollabRx's directors and executive officers is available in CollabRx's annual report on Form 10-K for the fiscal year ended March 31, 2015. Additional information about the interests of potential participants is included in the registration statement and proxy statement and other materials filed with the SEC. These documents are available free of charge at the SEC's website at www.sec.gov , or by going to CollabRx's Investors page on its corporate website at www.collabrx.com .

Additional Information

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. CollabRx has filed a registration statement on Form S-4, including a joint proxy statement of CollabRx and Medytox, and other materials with the SEC in connection with the Merger. We urge investors to read these documents because they contain important information. Investors may obtain free copies of the registration statement and proxy statement, as well as other filed documents containing information about Medytox and CollabRx, at www.sec.gov , the SEC's website, or by going to CollabRx's Investors page on its corporate website at www.collabrx.com .

About CollabRx, Inc.

CollabRx, Inc. (NASDAQ: CLRX ) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com .

Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances. The potential business combination referenced in this press release is subject to, among other things, stockholder approvals and other customary conditions. We cannot assure you that the contemplated business combination will be consummated.

CollabRx Contacts: Thomas R. Mika President & CEO CollabRx, Inc. 415-248-5350

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 274

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 173

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 252

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 237

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

UFP Industries Earnings Preview: What to Expect This Quarter

Updated Category News Views 165

UFP Industries Earnings Preview: What to Expect This Quarter UFP Industries (NASDAQ: UFPI) is gearing up for its upcoming quarterly earnings report. Investors are eager to learn about the financial health and performance of this leading supplier. Analysts project that UFP Industries will report earnings per share (EPS) of $1.86 in its upcoming announcement. Investors'...

Continue Reading
Fosun Highlights Innovations at CIIE Amid Global Opportunities

Updated Category News Views 101

Fosun Showcases Innovations at CIIE On November 5, the China International Import Expo (CIIE) commenced, marking a significant event for Fosun as a seven-time participant. This year's exhibition highlighted the company's commitment to innovation in healthcare, with impressive displays at its Fosun Pharma booth. Attendees were introduced to advanced medical devices and...

Continue Reading
Innovative DC Power Supplies Enhance Panasonic TOUGHBOOKs

Updated Category News Views 146

Introducing Havis DC Power Supplies for Mobile Workspaces Havis, Inc. has taken a significant step forward in rugged mobility solutions with the launch of their latest line of DC Power Supplies specifically designed for Panasonic TOUGHBOOK devices. These power supplies are essential for professionals who depend on reliability in challenging conditions. Why Choose Havis DC...

Continue Reading
Nvidia and UAE Collaboration: A New Era in AI Exports

Updated Category News Views 194

Nvidia's Stock Surge Following UAE AI Export Approval Nvidia (NASDAQ: NVDA) witnessed a remarkable rise in its stock value recently after the U.S. government greenlit billions in chip exports to the United Arab Emirates (UAE). This event is a significant milestone, marking the beginning of a collaboration focused on artificial intelligence and technology advancement. The...

Continue Reading
How Fed Decisions and Tech Sector Gains Shape Markets

Updated Category Markets Views 412

Surprising CPI data indicating a 3.3% increase in May led the Federal Reserve to maintain interest rates unchanged. The IT industry, meantime, soared, with Oracle seeing a big boost despite missing earnings estimates because of strong demand for its cloud services and Apple's stock rising because of new AI features. These developments point to robust investment prospects...

Continue Reading